Compare ADMA Biologics Inc (ADMA) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Riot Platforms Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Riot Platforms Inc trades at $20.94 (market cap $8.01B). The key difference: Riot Platforms Inc is far larger — about 3.8× ADMA Biologics Inc's market cap, and Riot Platforms Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | RIOT | |
|---|---|---|
Market Cap | $2.13B | $8.01B |
Sector | Health | Technology |
52-Week High | $20.38 | $28.67 |
52-Week Low | $7.60 | $11.03 |
Enterprise Value | $2.20B | $8.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
RIOT trades at $22.87, up 3.44% today, but technical indicators signal a bearish trend with resistance at $24. The company reported a net loss of $663.18 million in 2025 with negative cash flow from operations, though revenue reached $647.44 million. Recent news highlights volatility tied to Bitcoin price swings and a strategic pivot toward high-performance computing data centers, including a partnership with Terrestrial Energy for nuclear-powered facilities.
Wall Street analysts remain overwhelmingly bullish with a 94% buy rating and $27.83 consensus price target, but high valuation multiples and persistent losses pose significant risks. Investment appeal hinges on successful execution of the AI data center strategy amid competitive and regulatory pressures in the energy-intensive mining sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
